Studying CSF Element Profiles and Tear Fluid as Potential Biomarkers, and Novel and Combined Therapies for PD with Paul Lingor

Evidence supports that dysfunction in the homeostasis of iron and other elements likely contributes to the pathophysiological mechanisms of Parkinson's disease, but we have yet to develop suitable elemental biomarkers for use in diagnosing and monitoring the progression of Parkinson's disease. Dr. Paul Lingor discusses his work in this area to identify patterns of bioelements in CSF that could serve as PD biomarkers. Beyond CSF, he is also examining tear fluid as a potential biomarker source that is easier to collect. In addition to work on biomarkers, Paul has been involved in developing and evaluating new treatments for Parkinson's disease. In this episode, he discusses an ongoing phase II clinical trial evaluating the ROCK inhibitor Fasudil, as well as research examining combinations of advanced therapies for people with later-stage Parkinson's disease. Paul is Professor of Neurology at the Technical University of Munich and head of the outpatient clinics for motor neuron disease and co-head of the outpatient clinics for Parkinson’s disease.Mentioned in this episode:This podcast episode was part of a limited series created by The Michael J. Fox Foundation in 2023 and 2024 for clinicians and researchers in our audience.  These episodes provide a deeper dive into exciting new scientific research in Parkinson’s disease, as well as innovative tools and valuable resources, through conversations with a variety of experts in the field. We hope you enjoy the conversation.Researchers are studying the link between sense of smell and brain health. People with and without Parkinson's can help by taking a scratch-and-sniff test. It’s free, mailed to your home and takes just 15 minutes to complete. mysmelltest.org/getstarted